# SNGX catalysts: SOLIGENIX, INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/sngx/catalysts

> SOLIGENIX, INC. (SNGX) has no upcoming catalysts in this calendar. The latest recorded is the dusquetide topline data readout, August 26, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for SNGX?

SOLIGENIX, INC. (SNGX) has no upcoming catalysts in this calendar. The latest recorded is the dusquetide topline data readout, August 26, 2026. ClinicalTrials.gov: "NCT06386744 (Dusquetide for the Treatment of Behcet's Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-23 (ACTUAL); Lead Sponsor Soligenix; Results First Posted 2026-08-26." [Calendar and source filings](https://sec-api.dev/companies/sngx/catalysts)

Source: ClinicalTrials.gov, https://clinicaltrials.gov/study/NCT06386744?tab=results (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/companies/sngx/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | SOLIGENIX, INC. |
| Ticker | SNGX (Nasdaq) |
| SEC CIK | 812796 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/sngx |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Dec 2022 | [HyBryte (lymphoma) NDA/BLA submission](https://sec-api.dev/pdufa/lymphoma) | SNGX |  | completed | "In December 2022, we submitted the HyBryte™ NDA for the treatment of CTCL with the FDA." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/812796/000110465925108475/sngx-20250930x10q.htm)) |
| Apr 2023 | [HyBryte (lymphoma) NDA/BLA submission](https://sec-api.dev/pdufa/lymphoma) | SNGX |  | completed | "In April 2023, we had a Type A meeting with the FDA to clarify and respond to the issues identified in the RTF letter received from the FDA and to seek additional guidance concerning information that the FDA would require for a resubmitted NDA to be deemed acceptable to file, in order to advance HyBryte™ towards marketing approval and U.S. commercialization." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/812796/000110465926057904/sngx-20260331x10q.htm)) |
| Apr 2025 | [HyBryte (lymphoma) interim data readout](https://sec-api.dev/pdufa/lymphoma) | SNGX | early-stage CTCL | completed, positive | "In April 2025, we announced positive interim results from the ongoing open-label, IIS evaluating extended HyBryte™ treatment for up to 54 weeks in patients with early-stage CTCL." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/812796/000110465926057904/sngx-20260331x10q.htm)) |
| May 23, 2025 | [Dusquetide primary completion](https://sec-api.dev/pdufa/dusquetide) | SNGX | Behçet Disease | completed | "NCT06386744 (Dusquetide for the Treatment of Behcet's Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-23 (ACTUAL); Lead Sponsor Soligenix; Results First Posted 2026-08-26." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06386744)) |
| October 22, 2025 | [Hypericin primary completion](https://sec-api.dev/pdufa/hypericin) | SNGX | Psoriasis; Plaque Psoriasis; Psoriasis Vulgaris | completed | "NCT05442190 (Topical SGX302 for Mild-to-Moderate Psoriasis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-22 (ACTUAL); Lead Sponsor Soligenix." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05442190)) |
| Q2 2026 | [Psoriasis interim data readout](https://sec-api.dev/pdufa/psoriasis) | SNGX |  | scheduled | "A confirmatory, placebo-controlled Phase 3 study based upon an EMA-accepted protocol is actively enrolling with interim analysis expected in the second quarter of 2026 and top-line results expected in the second half of 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/812796/000110465926037701/sngx-20251231x10k.htm)) |
| Q2 2026 | [HyBryte (lymphoma) interim data readout](https://sec-api.dev/pdufa/lymphoma) | SNGX | CTCL and updated our enrollment progress to 66 patients in February of 2026 | scheduled | "In November 2025, we successfully completed the planned enrollment of 50 patients necessary for the planned interim analysis in the second quarter of 2026 for our confirmatory Phase 3 study evaluating HyBryte™ in the treatment of CTCL and updated our enrollment progress to 66 patients in February of 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/812796/000110465926037701/sngx-20251231x10k.htm)) |
| May 22, 2026 | [Hypericin primary completion](https://sec-api.dev/pdufa/hypericin) | SNGX | CTCL/ Mycosis Fungoides; CTCL; Mycosis Fungoides | withdrawn | "NCT06470451 (Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-05-22 (ACTUAL); Lead Sponsor Soligenix." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06470451)) |
| 2H 2026 | [SOLIGENIX, INC. topline data readout](https://sec-api.dev/companies/sngx/catalysts) | SNGX |  | scheduled | "This confirmatory 18-week study, expected to enroll approximately 80 patients across the U.S. and Europe, began patient enrollment in December 2024, with top-line results anticipated in the second half of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/812796/000155837025011554/sngx-20250630x10q.htm)) |
| 2H 2026 | [Hypericin topline data readout](https://sec-api.dev/pdufa/hypericin) | SNGX | CTCL with top-line results | scheduled | "We anticipate top-line results in the second half of 2026." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/812796/000110465926006255/tm263784-1_424b5.htm)) |
| 2H 2026 | [HyBryte (lymphoma) topline data readout](https://sec-api.dev/pdufa/lymphoma) | SNGX | CTCL with top-line results | scheduled | "In December 2024, we opened patient enrollment for our confirmatory Phase 3 study evaluating HyBryte™ (synthetic hypericin) in the treatment of CTCL with top-line results anticipated in the second half of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/812796/000110465926057904/sngx-20260331x10q.htm)) |
| August 26, 2026 | [Dusquetide topline data readout](https://sec-api.dev/pdufa/dusquetide) | SNGX | Behçet Disease | completed | "NCT06386744 (Dusquetide for the Treatment of Behcet's Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-23 (ACTUAL); Lead Sponsor Soligenix; Results First Posted 2026-08-26." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06386744?tab=results)) |

## Drugs

- [Cancer](https://sec-api.dev/pdufa/cancer): 
- [Dusquetide](https://sec-api.dev/pdufa/dusquetide): Behçet Disease
- [Hypericin](https://sec-api.dev/pdufa/hypericin): ctcl with top-line results, CTCL/ Mycosis Fungoides, Psoriasis
- [HyBryte (lymphoma)](https://sec-api.dev/pdufa/lymphoma): early-stage ctcl, ctcl with top-line results, ctcl and updated our enrollment progress to 66 patients in february of 2026
- [Psoriasis](https://sec-api.dev/pdufa/psoriasis): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/sngx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "SNGX catalysts: SOLIGENIX, INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/sngx/catalysts

```bibtex
@misc{secapidev_companies_sngx_catalysts_20261116,
  title        = {SNGX catalysts: SOLIGENIX, INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/sngx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_sngx_catalysts_20261116","title":"SNGX catalysts: SOLIGENIX, INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/sngx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
